Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"Softigel Procaps","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Engages Procaps for Development and Production of CannAmide\u2122 and its SCI-110 Product Candidate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"COLOMBIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Softigel Procaps

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.

            Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide

            Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: SciSparc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY